Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GSR | P00390 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.30 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.30 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.30 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.30 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4129 | 0.74 | TSHR (0.47) | ALDH1A1TSHRLMNACES2CES1 | |
| SCHEMBL29404220 | 0.74 | TSHR (0.47) | ALDH1A1TSHRLMNACES2CES1 | |
| Benzene SCHEMBL28042388 | 0.72 | LMNA (0.45) | ALDH1A1TSHRLMNACES2CES1 | |
| SCHEMBL28117905 | 0.72 | TSHR (0.45) | ALDH1A1TSHRLMNACES2CES1 | |
| SCHEMBL14217841 | 0.70 | TSHR (0.43) | ALDH1A1TSHRLMNACES2CES1 | |
| SCHEMBL23219858 | 0.67 | TRPV6 (0.50) | ALDH1A1TSHRLMNAORAI1ORAI2 | |
| 1,2-Dichlorobenzene SCHEMBL28043924 | 0.67 | TSHR (0.71) | ALDH1A1TSHRLMNACYP1A2CES2 | |
| SCHEMBL1186935 | 0.67 | TSHR (0.39) | ALDH1A1TSHRLMNACES2CES1 | |
| SCHEMBL16104430 | 0.67 | ENPP2 (0.45) | ALDH1A1TSHRLMNAHPGDCES2 | |
| Chlorobenzene SCHEMBL28220118 | 0.65 | TSHR (0.55) | ALDH1A1TSHRLMNACYP1A2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393856-B2 | Anti-viral uses of borinic acid complexes | ANACOR PHARMACEUTICALS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| EP-1771182-A1 | ANTI-PARASITIC USES OF BORINIC ACID COMPLEXES | Anacor Pharmaceuticals, Inc. (US) | 2007-04-11 | — | — | EP | disclosed |
| EP-1765360-A2 | ANTI-VIRAL USES OF BORINIC ACID COMPLEXES | Anacor Pharmaceuticals, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006085932-A2 | ANTI-VIRAL USES OF BORINIC ACID COMPLEXES | ANACOR PHARMACEUTICALS, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| US-20060019927-A1 | Anti-viral uses of borinic acid complexes | ANACOR PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | disclosed |
| US-20060014723-A1 | Anti-parasitic uses of borinic acid complexes | ANACOR PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005123095-A1 | ANTI-PARASITIC USES OF BORINIC ACID COMPLEXES | ANACOR PHARMACEUTICALS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014723-A1 | Anti-parasitic uses of borinic acid complexes | BPGM, HRH1, HRH3 | ALDH1A1 2879/4885TSHR 3633/4885LMNA 928/4885 |
| US-20060019927-A1 | Anti-viral uses of borinic acid complexes | SSB, BPGM, HAVCR2 | ALDH1A1 3836/4885TSHR 4453/4885LMNA 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.